Patient Management and Literature Analysis Case Study Answer

Patient Presentation

The patient under consideration presents a complex medical history, with severe spinal canal stenosis, radiculopathy, claudication, atrial fibrillation (AF) managed with flecainide and apixaban, congestive heart failure (CCF), hypercholesterolemia, obesity, chronic obstructive pulmonary disease (COPD), chronic pain, and depression. Notably, a history of difficult intubation adds a layer of caution to any procedural or postoperative interventions. The current medication regimen comprises Nexium, flecainide, rosuvastatin, apixaban, frusemide, diltiazem, Effexor, telmisartan, beztri (budesonide, glycopyrrolate, formoterol), ventolin, Panadol osteo, vitamin D, and vitamin C. Known allergies include augmentin duo, sulfurs, and opiates.

In the intraoperative setting, the patient underwent a 4-hour surgery under general anaesthesia with vecuronium, etSev. The hemodynamics revealed unsupported sinus rhythm, and the intubation process, graded as 3b, presented a challenge mitigated by manageable bag-mask ventilation. Pain management during the procedure involved a combination of methadone, clonidine, and oxycodone. Prophylactic measures were taken with the administration of cefazolin as an antibiotic. Intravenous fluids, specifically 1L crystalloid, were judiciously administered to maintain fluid balance.

Postoperatively, the patient experienced hypotension, prompting immediate intervention. Fluid resuscitation, utilising crystalloid and 4% albumin, was initiated alongside a unit of red blood cells (RBC) due to a haemoglobin level of 90, strategically addressing intravascular volume optimisation and anaemia-associated hypotension. Recognising the need for vasopressor support, metaraminol was introduced for its vasoconstrictive effects, augmenting systemic vascular resistance and cardiac output. In response to the critical condition, the patient was promptly admitted for intensified monitoring and a comprehensive approach to hypotension management. This integrated strategy addressed multifactorial contributors to the postoperative hypotensive episode and ensured timely and tailored care.

A multidisciplinary strategy was required to address the patient's chronic hypotension during the postoperative period. The cornerstone of this strategy was the patient's ongoing metaraminol administration, which underscores the critical and continued necessity for vasopressor support. Additionally, the management approach gave considerable weight to pain management, utilising oxycodone (Orca) to improve patient comfort as well as a prophylactic against future stress-related hypotension exacerbations.

The patient continued to have hypotension on the first postoperative day. She also had a high fever (38.0), and when she tried to sit out of bed, her blood pressure dropped drastically. The patient was immediately placed on a sepsis care pathway upon recognition of the possibility of sepsis. This required extensive research, including microbiological analyses and blood cultures. Nevertheless, the findings of these studies were unsatisfactory. A comprehensive and integrated strategy characterised the overall management of the hypotensive episode. This encompassed fluid resuscitation, blood transfusion, vasopressor therapy, and meticulous consideration of potential sepsis.

 The care plan was tailored to the intricacies of the patient's medical history, particularly the history of difficult intubation, showcasing a nuanced understanding of the individualised challenges and requirements. Close monitoring of vital signs, fluid balance, and ongoing laboratory results was pivotal in this adaptive approach. This real-time assessment facilitated dynamic adjustments to the treatment plan, ensuring that interventions aligned with the evolving clinical dynamics. The patient's response to therapeutic measures guided the ongoing optimisation of the care plan, emphasising a patient-centred and responsive approach to postoperative care.

Literature Analysis

Vasopressors with metaraminol are pivotal in critically ill patients' intricate and dynamic management, particularly in the challenging context of shock (Grauslyte et al., 2022). Shock, a life-threatening condition characterised by insufficient tissue perfusion and oxygen delivery, demands rapid and precise interventions, making vasopressors indispensable in critical care (Koya & Paul, 2023). As a strong alpha-adrenergic agonist, metaraminol is categorised as a sympathomimetic amine. Its main mechanism of action is the activation of vascular smooth muscle's alpha-1 receptors, which causes vasoconstriction. This mechanism becomes paramount in reversing hypotension, a common manifestation of shock, ultimately restoring systemic vascular resistance and blood pressure (Taylor & Cassagnol, 2022). Metaraminol's importance extends beyond its capacity to raise blood pressure; it also promotes organ perfusion, which is essential for reducing the catastrophic consequences of shock (Grauslyte et al., 2022).

For the patient in the case study with a complex medical history, metraminol is crucial in controlling the postoperative hypotensive episode. Because of its vasoconstrictive qualities improve systemic vascular resistance, which is essential for optimising blood pressure when severe spinal canal stenosis, obesity, and chronic pain are present. Furthermore, atrial fibrillation and congestive heart failure patients benefit most from metaraminol's capacity to increase cardiac output (Kotecha & Piccini, 2015). The medication's inclusion in the treatment plan guarantees a customised strategy that meets each patient's unique requirements. Its critical importance in addressing multiple causes of hypotension, in conjunction with blood transfusion and fluid resuscitation, is highlighted by its inclusion in a comprehensive strategy. Metaraminol's adjustability enables precision control, which is essential for keeping an eye on the patient's reaction and guaranteeing ideal hemodynamic stability (Grauslyte et al., 2022).

This literature analysis sheds light on the findings of five key studies conducted by Sardaneh et al. (2021 and 2022), Grauslyte et al. (2022), Lee et al. (2017), Russel (2019), and Vijay et al. (2016). These studies provide insights into the utilisation, safety profile, and comparative effectiveness of vasopressors, with a specific focus on metaraminol, in various clinical contexts.

To evaluate the pharmacoepidemiology of metaraminol use in critically sick patients managing shock, Sardaneh et al. (2021) conducted a retrospective observational study in an intensive care unit (ICU) in Sydney, Australia. As part of the research, 152 people got intravenous infusions of metaraminol over one year. Important data revealed that 53% of patients received metaraminol as a monotherapy, and 97% had it as their first-line vasopressor. As the most widely used first-line vasopressor, metraminol has emerged. The fact that no extravasation injuries were observed for a median of 7 hours during infusion emphasised the safety profile of metaraminol in the research.

Grauslyte et al. (2022) extended their examination of the use of metaraminol to thirty critical care units in the United Kingdom. In response to the study, 26 units provided data. Of those, 88% utilised metaraminol, and roughly 62% said that in critical care circumstances, it was their first choice vasopressor. The study indicated a notable discrepancy between clinical practice and the body of available scientific literature, even though metaraminol is widely used to treat shock. It also revealed a sizable gap in the data supporting the drug's safety and effectiveness.

In response to this disparity, a systematic investigation of the comparative efficacy and safety of metaraminol was carried out by Sardaneh et al. (2022). The review comprised three observational studies and one controlled trial with fifty-four adult patients of different forms of shock. According to the survey, the metaraminol and noradrenaline groups did not significantly vary in-hospital mortality. Crucially, the included trials did not report any adverse pharmacological events or responses due to infusion, supporting metaraminol's potential safety in shock therapy.

Sardaneh et al. (2021) compared patients receiving metaraminol monotherapy to those getting it in conjunction with other vasopressors to investigate the relative effectiveness of metaraminol in addition to its prevalence and safety. According to the study, monotherapy patients had shorter overall vasopressor usage times in the intensive care unit (ICU) and a lower Acute Physiology and Chronic Health Evaluation III score than patients receiving combination medication. This study offers important insights into how choosing vasopressor therapy techniques may affect patient outcomes.

On the other hand, Grauslyte et al. (2022) identified a notable discrepancy between clinical practice and the body of accessible scientific research by pointing out a sizable gap in the evidence supporting the safety and effectiveness of metaraminol in treating shock. The report recommends more research to confirm the usefulness of metaraminol in treating critically ill patients and clarify its safety profile. This research should include service evaluations, observational studies, and prospective randomised controlled trials. The focus was moved to certain clinical situations by Lee et al. (2017), specifically spinal-induced hypotension in obstetric patients undergoing cesarean delivery under spinal anaesthesia. The study clarified that adding vasopressor medication is necessary since fluid administration alone cannot completely reverse hypotension. Due to its quick onset and brief half-life, the vasopressor phenylephrine has become a key component for the management and prevention of spinal-induced hypotension in obstetric patients.

The study recommended fixed-rate phenylephrine infusion regimens to maintain systolic blood pressure within a specific range, noting the correlation between such regimens and the reduction in physician interventions needed. The combined-spinal epidural technique (CSE) was advocated for low-dose spinal anaesthesia, allowing flexibility for administering epidural local anaesthetics if required. The findings challenged historical approaches that leaned towards fluid therapy, emphasising the effectiveness of vasopressors, particularly phenylephrine, in preventing and treating spinal-induced hypotension.

Russel's (2019) paper comprehensively reviewed vasopressors in critically ill patients with shock. The review covered various aspects, including the pathophysiology of vasopressor effects, factors influencing vasopressor dose, and potential biomarkers. The paper evaluated evidence quality using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) framework. The review emphasised that no randomised controlled studies showed a substantial difference in 28-day mortality rates despite the widespread use of vasopressors, especially norepinephrine and metaraminol, as the first-choice vasopressor in vasodilatory shock. The study covered norepinephrine dose-lowering tactics such as vasopressin and angiotensin II, which did not result in a drop in mortality.

Nonetheless, in certain trials, corticosteroids showed a noteworthy decrease in 28-day mortality. The study also examined other vasopressors, including dopamine, epinephrine, dobutamine, and vasopressin, and it offered suggestions for how to utilise them in particular clinical situations. The review also covered newly developed vasopressors, such as selepressin, which provides insight into the possible directions of vasopressor therapy.

 An alternative approach to vasopressor management was investigated by Vijay et al. (2016), who evaluated the effects of preventing patients receiving elective or non-urgent surgery from receiving angiotensin-converting enzyme inhibitors (ACEi) and angiotensin II receptor blockers (ARB) on intraoperative hypotension, acute kidney injury (AKI), and postoperative atrial fibrillation (AF). Patients receiving chronic daily ACEi/ARB medication were the focus of the study; patients having emergency surgery within 12 hours of admission were not included.

Three hundred twenty-three patients were enrolled in the trial; 240 individuals continued taking their ACEi/ARB drugs, while 83 patients had their prescription withdrawn on the morning of surgery. In the withheld group, the interval between the previous dosage and surgery was longer (28 hours) than in the continued group (5.6 hours). However, there were no statistically significant differences between the two groups regarding intraoperative hypotension, metaraminol, or IV fluid doses. Secondary endpoints, including postoperative AKI and AF rates, did not differ significantly between the continued and withheld groups. The statistical analysis employed various tests, such as unpaired Student's t-tests, Mann-Whitney U test, Pearson chi-square tests, Spearman rank-order correlation, and multiple regression analysis. Despite the longer duration from the last dose to surgery in the withheld group, there were no apparent adverse effects observed in terms of hypotension, AKI, or AF. The study's results suggest that withholding ACEi/ARB on the morning of surgery did not lead to increased intraoperative complications or postoperative adverse events in the studied patient population.

In conclusion, this comprehensive literature analysis thoroughly overviews vasopressors' utilisation, safety, and comparative effectiveness in critical care, specifically focusing on metaraminol. The studies collectively highlight metaraminol's widespread use as a first-line vasopressor and emphasise its potential safety in managing various types of shock. However, the identified gap in evidence supporting its efficacy underscores the need for further research to validate its role in treating critically unwell patients.

The comparative effectiveness studies by Sardaneh et al. (2021) and Grauslyte et al. (2022) contribute valuable insights into the differences in patient outcomes based on vasopressor treatment strategies. Lee et al.'s (2017) study on spinal-induced hypotension in obstetric patients underscores the importance of vasopressor therapy, particularly phenylephrine, in specific clinical scenarios. Russel's (2019) comprehensive review provides a holistic understanding of vasopressors, evaluating evidence quality and discussing novel agents in development. Finally, Vijay et al.'s (2016) study adds to the diversity of the literature by examining the impact of withholding ACEi/ARB on intraoperative complications.

These studies significantly advance our understanding of vasopressor therapy, influencing clinical guidelines for caring for critically sick patients in shock and directing future research. Deciphering the intricacies of vasopressor utilisation, these discoveries lay the groundwork for evidence-based approaches while identifying avenues for additional research. This highlights the value of continuing research to improve and optimise our use of vasopressor medication and its importance in maximising patient outcomes in critical care settings.

Evaluation - Consider the Treatment According to the Literature Review 

The patient depicted in the case study had a complicated medical history that included depression, chronic pain, atrial fibrillation (AF), obesity, congestive heart failure (CCF), significant spinal canal stenosis, and chronic obstructive pulmonary disease (COPD). The patient experienced a hypotensive episode after surgery, which called for a thorough management strategy that included fluid resuscitation, blood transfusions, and the start of metaraminol. This multimodal approach underscores the necessity for customised interventions in critical care settings by reflecting the complexity of managing hypotension in patients with various comorbidities. The principal approaches utilised in the patient's care were in line with accepted critical care principles and with important conclusions from the literature about using vasopressors, including metaraminol. Fluid resuscitation with intravenous fluids (CSL 100 ml/hr) and 500 ml of 4% albumin was the first tactic. This was consistent with the basic theory that intravascular volume can be increased to cure hypotension. The literature backs up this strategy by emphasising how vital fluid resuscitation is to improving cardiac output and restoring intravascular volume in critically unwell patients (Koya & Paul, 2023).

A haemoglobin level of 90 is equivalent to one unit of red blood cells (RBC), which aligns with recommendations from the literature for treating hypotension by maximising tissue perfusion and oxygen-carrying capacity (Russel, 2019). The literature underscores the crucial role of optimising oxygen delivery, particularly in the context of underlying comorbidities. This approach ensures that the patient's hemodynamic stability is supported by adequate oxygen supply, addressing a fundamental aspect of managing hypotensive episodes. The alignment with established literature emphasises the importance of evidence-based practices in tailoring interventions to the specific needs of patients experiencing complex medical conditions. The initiation of metaraminol, a potent alpha-1 adrenergic agonist, was a crucial aspect of the patient's management and aligned with the literature's emphasis on vasopressors in managing hypotension, particularly in the challenging context of shock (Grauslyte et al., 2022). Metaraminol's vasoconstrictive qualities make it a valuable tool in reversing hypotension by activating vascular smooth muscle alpha-1 receptors, ultimately restoring systemic vascular resistance and blood pressure (Taylor & Cassagnol, 2022).

However, the patient's management also demonstrated variations from the literature findings. The development of a high fever (38.0) and postural drop in blood pressure triggered the initiation of a sepsis pathway. This consideration about metaraminol use might have yet to be explicitly discussed in the literature. The literature often focuses on the role of vasopressors in addressing hemodynamic instability without explicit discussions of sepsis pathways. The initiation of a sepsis pathway underscores the clinical reality that patients may present with multifactorial causes of hypotension, necessitating a comprehensive and individualised approach. These variations in management could be attributed to the patient's unique and complex medical history. The literature often provides general guidelines based on controlled studies, while individual patient presentations may require nuanced and tailored interventions. In the case of the patient with severe spinal canal stenosis, obesity, and multiple comorbidities, the initiation of a sepsis pathway might be a proactive measure to explore potential sources of infection that could contribute to hemodynamic instability.

References

Grauslyte, L., Phull, M., & Jovaisa, T. (2022). The use of metaraminol as a vasopressor in critically unwell patients: A narrative review and a survey of UK practice. Journal of Cardiothoracic and Vascular Anesthesia , 36 , S21. https://intapi.sciendo.com/pdf/10.2478/jccm-2022-0017

Kotecha, D., & Piccini, J. P. (2015). Atrial fibrillation in heart failure: What should we do? European Heart Journal , 36 (46), 3250-3257. https://doi.org/10.1093/eurheartj/ehv513

 Koya, H.H. & Paul, M. (2023). Shock. In StatPearls [Internet] . StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK531492/

Lee, J. E., George, R. B., & Habib, A. S. (2017). Spinal-induced hypotension: Incidence, mechanisms, prophylaxis, and management: Summarizing 20 years of research. Best Practice & Research Clinical Anaesthesiology , 31 (1), 57-68. https://doi.org/10.1016/j.bpa.2017.01.001

Russell, J. A. (2019). Vasopressor therapy in critically ill patients with shock. Intensive Care Medicine , 45 , 1503-1517. https://doi.org/10.1007/s00134-019-05801-z

Sardaneh, A. A., Narayan, S., Penm, J., Oliver, M., Gattas, D., McLachlan, A. J., & Patanwala, A. E. (2022). Efficacy and safety of metaraminol in critically ill patients with shock: A systematic review. Journal of Pharmacy Practice and Research , 52 (2), 83-93. https://doi.org/10.1002/jppr.1786

Sardaneh, A. A., Penm, J., Oliver, M., Gattas, D., McLachlan, A. J., & Patanwala, A. E. (2021). Pharmacoepidemiology of metaraminol in critically ill patients with shock in a tertiary care hospital. Australian Critical Care , 34 (6), 573-579. https://doi.org/10.1016/j.aucc.2021.01.002

Taylor, B. N., & Cassagnol, M. (2022). Alpha adrenergic receptors. In StatPearls [Internet] . StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK539830/

Vijay, A., Grover, A., Coulson, T. G., & Myles, P. S. (2016). Perioperative management of patients treated with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers: A quality improvement audit. Anaesthesia and Intensive Care , 44 (3), 346-352. https://journals.sagepub.com/doi/pdf/10.1177/0310057X1604400305

You Might Also Like:-

Clinical Nurses’ Awareness and Caring Experiences for Patients with Cervical Cancer

Translational Medicine Assignment Help

NCS6100 Nursing Cultural Studies Assignment Sample

Looking For Complete Assignment Sample Get It On WhatsApp